Clinical trials: Patients With Major Depressive Disorder
Depressive Disorder
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression. The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in…
- Trial name
- NCT00250601
- Testing
- Saredutant succinate (SR48968C)
- Where
- United States
- Volunteers
- 460 people
- Sponsor
- Sanofi
Adjunct in the Treatment of Depressive Disorder
A Randomized, Open-Label, 52-Week Extension Study to Evaluate the Maintenance of Remission, Relapse Prevention, and Long-Term Safety of CreNeuroS™ in Patients With Major Depressive Disorder Who Achieved Remission Following an 8-Week Parent Study
This multicenter, randomized, open-label extension study will evaluate the maintenance of remission, relapse prevention, long-term clinical outcomes, and safety of CreNeuroS™ in participants with Major Depressive Disorder (MDD)…
- Trial name
- NCT07893002
- Testing
- No intervention, CreNeuroS™ CNS Fish Oil Plus Softgels, 1 capsule orally once daily, CreNeuroS™ CNS Fish Oil Plus Softgels, 2 capsule orally once daily
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Sichuan Credit Pharmaceutical Co., Ltd.
Major Depressive Disorder
A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD
The aim of this Phase 2a study in patients with MDD is to assess safety and tolerability and preliminary antidepressant efficacy.
- Trial name
- NCT06309277
- Testing
- GM-1020
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- Gilgamesh Pharmaceuticals
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Patient Tolerability Study of GSK163090
The purpose of this study is to determine the safety and tolerability of a new drug, GSK163090, which is being developed for the treatment of depression and anxiety disorders.
- Trial name
- NCT00559299
- Testing
- GSK163090
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Depressive Disorder
A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)
The purpose of the study is to evaluate the long-term efficacy and safety of Saredutant in patients with depression. The primary objective is to evaluate the efficacy and safety of Saredutant 100 mg once daily compared to placebo…
- Trial name
- NCT00336713
- Testing
- Saredutant (SR48968C)
- Where
- United States
- Volunteers
- 430 people
- Sponsor
- Sanofi
Bipolar Disorder in Remission, Major Depression in Remission
Seasonality, Chronotype, Impulsivity, and Suicidality in Mood Disorder Patients
The aim of the study is to examine the seasonal variation of suicidal ideation in patients with mood disorders and the trajectory of impulsivity and suicidal ideation in patients with higher seasonality.
- Trial name
- NCT07857213
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Istanbul University - Cerrahpasa
Major Depression
Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression
This study investigates the hypothesis that pindolol can accelerate the response to antidepressants in patients with major depression treated with venlafaxine.
- Trial name
- NCT00159146
- Testing
- Pindolol and venlafaxin
- Where
- Denmark
- Volunteers
- 31 people
- Sponsor
- Hillerod Hospital, Denmark
Major Depressive Disorder
Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder
To examine the efficacy and safety of aripiprazole versus placebo as an adjunctive therapy co-administered with either an selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) in…
- Trial name
- NCT00876343
- Testing
- Aripiprazole (Fixed dose), Aripiprazole (Titrated dose)
- Where
- 8 sites in Japan
- Volunteers
- 586 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Depressive Disorder, Major
Does Nurse Semi Structured Interview Added to a rTMS Improve Patients With Major Depressive Disorder?
Repeated Transcranial Magnetic Stimulation - R.TMS - is currently part of the treatment for depressive illness. This non-invasive technique is designed to stimulate certain areas of the cerebral cortex involved in this pathology.
- Trial name
- DESTIMCARE (NCT03436823)
- Testing
- nurse semi-structured interview, Music & Relaxation with eyes closed
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Rennes University Hospital
Severe Depression
Psilocybin and Depression
The main aim of the study is to investigate the possible long-term therapeutic effects of psilocybin on the symptoms of severe depression, as well as the brain mechanisms underlying these changes.
- Trial name
- Psilo101 (NCT03380442)
- Testing
- Psilocybin, Ketamine (Ketalar)
- Volunteers
- 60 people
- Sponsor
- University of Helsinki
Depression
B Vitamins in MTHFR Positive Patients With Major Depression: A Post Hoc Analysis of Findings
A randomized double-blind placebo controlled study of reduced B vitamins in patients with major depression who were positive for one or both of the common MTHFR polymorphisms was conducted between 8/1/2014 and 4/3/2015.
- Trial name
- BVMD (NCT02709668)
- Testing
- Enlyte
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- High Point Regional Health Systems
Major Depressive Disorder
A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder
This trial is a 52-week study to assess the safety of long-term use of brexpiprazole as adjunctive therapy in combination with an antidepressant.
- Trial name
- NCT03737474
- Testing
- Brexpiprazole
- Where
- Japan
- Volunteers
- 248 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder
Brief Multifamily Psychoeducation for Families of Patients With Chronic Major Depression
The purpose of this study is to examine the effectiveness of brief multifamily psychoeducation to relieve the psychological distress of families of patients with chronic major depression and to improve their family functioning.
- Trial name
- NCT01734291
- Testing
- Family psychoeducation
- Where
- Japan
- Volunteers
- 49 people
- Sponsor
- Nagoya City University
Diabetic Neuropathies, Depressive Disorder, Major
Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder
The primary objective is to evaluate, separately in diabetic polyneuropathic pain (DPNP) patients with and without co-morbid major depressive disorder (MDD), whether duloxetine given as 60 mg to 120 mg once daily (QD) leads to a…
- Trial name
- NCT00844194
- Testing
- Duloxetine 60 mg QD, Duloxetine 30 mg QD, Duloxetine 90 mg QD
- Where
- 25 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Depressive Disorders, Psychotic Disorders
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
Patients who participated in the previous trial 28130, who were eligible, were entered into this trial. Patients who were randomized to placebo in the previous trial 28130 continued on placebo while patients who were randomized…
- Conditions
- Depressive Disorders, Psychotic Disorders, Depression
- Trial name
- NCT00844922
- Testing
- SCH 900636
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Bipolar Depression
A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression
The main goal of this study is to help answer the following research question(s) and not to treat the child's illness. Can this study drug make children with bipolar depression feel better? Does this study drug work better than a…
- Trial name
- NCT00844857
- Testing
- Olanzapine Fluoxetine Combination (OFC)
- Where
- 7 sites in United States, Russia
- Volunteers
- 291 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
8-week of PS128 RCT in Patients With Major Depressive Disorder
Background: Recent studies have suggested that gut-brain axis may be one of the mechanisms of major depression disorder. In animal studies, alteration of gut microbiota can affect animal's depression or anxiety-like behavior…
- Trial name
- NCT04199845
- Testing
- PS128
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taipei Medical University WanFang Hospital
Bipolar Disorder, Major Depressive Disorder
A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression.
We hypothesize that depressed patients who have not responded to their current antidepressant medication will respond to the addition of ropinirole to their current regimen at a rate better than placebo.
- Trial name
- NCT00335205
- Testing
- ropinirole
- Where
- 2 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Sheba Medical Center
Depressive Disorder, Major
Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder
To evaluate the early onset of efficacy of vortioxetine 17 mg intravenously (IV) and vortioxetine 10 mg/day oral dose regimen versus placebo IV and vortioxetine 10 mg/day oral dose regimen on depressive symptoms
- Trial name
- NCT02919501
- Testing
- Vortioxetine (IV), Vortioxetine (tablet)
- Where
- 7 sites in Estonia, Finland
- Volunteers
- 55 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder
This study is to compare the pharmacokinetics of FK949E low dose tablets and FK949E high dose tablets in non-elderly patients with major depressive disorder. The safety of FK949E in the population was also evaluated.
- Trial name
- NCT01919008
- Testing
- FK949E
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Astellas Pharma Inc